Impact of the Healthcare Reform in the United States (ObamaCare) on the Pharmaceutical Business
ObamaCare changes have different influence on diverse healthcare business. Pharmaceutical industry seems to gain on this reform unlike the insurance business. In this article we briefly present the main positive and negative effects of health reform in the US. Then, we point to the impact of ObamaCare on profits, costs and activities of pharmaceutical companies. We discuss changes such as: increase in sales of prescription drugs; new rules of registration of generic drugs; novel tax on sales of original drugs; incentives for pharma to put more attention to specific fields in R&D; bigger transparency in relations between physicians and pharma industry.